SEC Form 4 · accession 0001179110-17-011060
Theravance Biopharma, Inc. · TBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shehnaaz Suliman
Officer — SVP, Corp Dev & Strategy
Period of report
Aug 1, 2017
Accepted (ET)
Aug 3, 2017 · 6:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001583107
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Aug 1, 2017 | A | 20,000 | $0.00 | A | 20,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1 | $31.93 | Aug 1, 2017 | A | 170,000 | A | — | Jul 31, 2027 | Ordinary Shares | 170,000 | 170,000 | D |
Explanation of responses
- F1This option may be exercised with respect to the first 25% of the shares subject to this option when optionee completes 12 months of continuous service after the Grant Date. This option may be exercised with respect to an additional 1/48th of the shares subject to this option when optionee completes each month of continuous service thereafter. The option shall be fully vested and exercisable on the 4-year anniversary of the Grant Date provided optionee has remained in continuous service through such date.